📇 Rhumatologue · MULHOUSE · (68) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
110.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
33
33 articles ont été cités au moins 33fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
3 639
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
251
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
90
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Identification of bottom deformations of the ocean from surface measurements
2025ArticleInverse Problems and Imaging
Parametric study of turbulence ingestion noise for marine propellers
2025CongrèsForum Acusticum 2025 - 11th Convention of the European Acoustics Association/EuroNoise 2025
An inverse problem related to an elasto-plastic beam
2025ArticleInverse Problems
Table ronde - Le rôle des sciences dans les politiques publiques de l’environnement
2025Congrès37èmes Journées Scientifiques de l'Environnement - (Co)habiter la Terre
Enhanced quantitative precipitation estimation through the opportunistic use of Ku TV-SAT links via a dual-channel procedure
2025ArticleAtmospheric Measurement Techniques
Efficient boundary integral method to evaluate the acoustic scattering from coupled fluid-fluid problems excited by multiple sources
2025ArticleJournal of Computational Physics
Computation of Green's functions for the acoustic scattering by an elastic structure excited by a turbulent flow in water
2024CongrèsINTER-NOISE and NOISE-CON 2024 - 53nd International Congress and Exposition on Noise Control Engineering
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers
2024ArticleClinical Pharmacology and Therapeutics
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
SERVICE DE SOINS SNCF
10 BD LEON GAMBETTA, 68100 MULHOUSE
CABINET DU DR FRANCOIS MERCIER
1 RUE DU COUVENT, 68100 MULHOUSE
CABINET DU DR FRANCOIS MERCIER
MAISON DE SANTE DES ERRUES 2 BIS RUE DU TRAMWAY, 90150 MENONCOURT
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
Purpose: Model-based tumor growth inhibition (TGI) metrics are increasingly incorporated into go/no-go decisions in early clinical studies. To apply this methodology to new investigational combinations requires independent evaluation of TGI metrics in recently completed Phase III trials of effective immunotherapy. Patients and Methods: Data were extracted from IMpower150, a positive, randomized, Phase III study of first-line therapy in 1,202 patients with non–small cell lung cancer. We resampled baseline characteristics and longitudinal sum of longest diameters of tumor lesions of patients from both arms, atezolizumab+ bevacizumab+chemotherapy (ABCP) versus BCP, to mimic Phase Ib/II studies of 15 to 40 patients/arm with 6 to 24 weeks follow-up. TGI metrics were estimated using a bi-exponential TGI model. Effect sizes were calculated as TGI metrics ratio of medians (MedR), objective response rate (ORR) difference (d), and progression-free survival (PFS), hazard ratio (HR) between arms. Correct and incorrect go decisions were evaluated as the probability to achieve desired effect sizes in ABCP versus BCP and BCP versus BCP, respectively, across 500 replicated subsamples for each design. Results: For 40 patients/24 weeks follow-up, correct go decisions based on probability tumor growth rate (KG) MedR <0.90, dORR >0.10, and PFS HR <0.70 were 83%, 69%, and 58% with incorrect go decision rates of 4%, 12%, and 11%, respectively. For other designs, the ranking did not change with TGI metrics consistently overperforming RECIST endpoints. The predicted overall survival (OS) HR was around 0.80 in most of the scenarios investigated. Conclusions: Model-based estimate of KG MedR is an exploratory endpoint that informs early clinical decisions for combination studies.
Cell reports. Medicine · 2023
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Statistics in medicine · 2026 · Journal Article
Kazantzidis G, Mercier F, Rondeau V
Journal of visualized experiments : JoVE · 2025 · Journal Article
Gife V, Sharif-Askari B, Sadr Hashemi Nejad A, Aloyz R, et al.
Statistics in medicine · 2025 · Journal Article
Alvares D, Barrett JK, Mercier F, Roumpanis S, et al.
Clinical pharmacology and therapeutics · 2024 · Journal Article
Benzekry S, Karlsen M, Bigarré C, Kaoutari AE, et al.
Statistics in medicine · 2024 · Journal Article
Alvares D, Mercier F
CPT: pharmacometrics & systems pharmacology · 2024 · Journal Article
Marchand M, Gonçalves A, Mercier F, Chanu P, et al.
Statistical methods in medical research · 2023 · Journal Article
Yiu S, Wang Q, Mercier F, Manfrini M, et al.
Biometrics · 2023 · Journal Article
Kerioui M, Beaulieu M, Desmée S, Bertrand J, et al.
Blood advances · 2023 · Journal Article
Kfoury YS, Ji F, Jain E, Mazzola M, et al.
Cell reports. Medicine · 2023 · Journal Article
Maru B, Messikommer A, Huang L, Seipel K, et al.
Statistics in medicine · 2022 · Journal Article
Braun TM, Mercier F
Frontiers in pharmacology · 2022 · Journal Article
Salame N, Fooks K, El-Hachem N, Bikorimana JP, et al.
Diagnostics (Basel, Switzerland) · 2022 · Journal Article
Menkovic I, Boutin M, Alayoubi A, Curado F, et al.
Journal of proteome research · 2022 · Journal Article
Menkovic I, Boutin M, Alayoubi A, Curado F, et al.
Contemporary clinical trials communications · 2022 · Journal Article
Micallef S, Sostelly A, Zhu J, Baverel PG, et al.
British journal of clinical pharmacology · 2022 · Journal Article
Kerioui M, Bertrand J, Bruno R, Mercier F, et al.
Investigational new drugs · 2022 · Journal Article
Meneses-Lorente G, Fowler S, Guerini E, Kowalski K, et al.
European journal of drug metabolism and pharmacokinetics · 2021 · Journal Article
Djebli N, Buchheit V, Parrott N, Guerini E, et al.
Leukemia & lymphoma · 2021 · Journal Article
Bazinet A, Rys RN, Barry A, Greenwood CMT, et al.
Cold Spring Harbor molecular case studies · 2021 · Journal Article
Bazinet A, Heath J, Chong AS, Simo-Cheyou ER, et al.
Cell reports · 2023 · Journal Article
Neault M, Lebert-Ghali CÉ, Fournier M, Capdevielle C, et al.
Cancer chemotherapy and pharmacology · 2023 · Journal Article
Meneses-Lorente G, Guerini E, Mercier F, Parrott N, et al.
Cancer chemotherapy and pharmacology · 2021 · Clinical Trial, Phase I
González-Sales M, Djebli N, Meneses-Lorente G, Buchheit V, et al.
British journal of cancer · 2023 · Journal Article
Bruno R, Chanu P, Kågedal M, Mercier F, et al.
Bioanalysis · 2022 · Case Reports
Menkovic I, Boutin M, Alayoubi A, Curado F, et al.
Molecular genetics and metabolism reports · 2025 · Journal Article
Rizzolo A, Miron MC, Delisle JF, Alos N, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · Clinical Trial, Phase III
Bruno R, Marchand M, Yoshida K, Chan P, et al.
CPT: pharmacometrics & systems pharmacology · 2026 · Journal Article
Fochesato A, Brooks L, Bazgir O, Pierrillas PB, et al.
Cancer chemotherapy and pharmacology · 2022 · Journal Article
Mercier F, Djebli N, González-Sales M, Jaminion F, et al.
Molecular genetics and metabolism reports · 2025 · Journal Article
Rizzolo A, Miron MC, Delisle JF, Alos N, et al.
Discovering material information using hierarchical Reformer model on financial regulatory filings
Most applications of machine learning for finance are related to forecasting tasks for investment decisions. Instead, we aim to promote a better understanding of financial markets with machine learning techniques. Levera
sj-R-1-smm-10.1177_09622802231212274 - Supplemental material for Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes
Supplemental material, sj-R-1-smm-10.1177_09622802231212274 for Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes by Sean
sj-R-1-smm-10.1177_09622802231212274 - Supplemental material for Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes
Supplemental material, sj-R-1-smm-10.1177_09622802231212274 for Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes by Sean
Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes
In clinical development, it is useful to characterize the causal relationship between individual drug concentrations and clinical outcomes in large phase III trials of new therapeutic agents because it can provide insigh
Clustering-Based Outcome Models for Clinical Studies: A Scoping Review
This review provides a systematic overview of methods that combine covariate-based clustering of observational units (patients) with outcome models for clinical studies. We distinguish between informed-cluster models, wh
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
Abstract Background Acute myeloid leukemia (AML) is an aggressive hematological cancer resulting from uncontrolled proliferation of differentiation-blocked myeloid cells. Seventy percent of AML patients are currently not
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).